Prognosis in Small Cell Carcinoma of the Lung--relationship to Human Milk Fat Globule 2 (HMFG2) Antigen and Other Small Cell Associated Antigens

Overview

Journal Br J Cancer

Specialty Oncology

Date 1987 Oct 1

PMID 2825751

Citations 4

Authors

S G Allan

F G Hay

M A McIntyre

R C Leonard

Affiliations

Soon will be listed here.

Abstract

Forty fixed tissue sections from patients with small cell lung carcinoma (SCCL) have been stained with a panel of 10 monoclonal antibodies using a peroxidase anti-peroxidase method and the incidence of staining has been compared to patient characteristics at presentation and to survival. An inverse association between HMFG2 staining and survival was found with median survival in HMFG2 negative patients 13 months compared to 8 months for HMFG2 positive patients. No such association was found with the other antibodies and no association was found between staining and disease extent or primary versus secondary deposits with this panel of antibodies. Epidermal growth factor receptor was detected in 3/38 presentation biopsies and in these 3 patients mean survival was only 5 months. Further prospective study of HMFG2 as a prognostic indicator in SCCL is suggested.

Citing Articles

Small cell lung cancer.

Leonard R Br J Cancer. 1989; 59(4):487-90.

PMID: 2540787 PMC: 2247163. DOI: 10.1038/bjc.1989.101.

Expression of 'small cell carcinoma antigens' in primary small cell lung cancer and metastases: an immunohistochemical study.

Skov B, Hirsch F, Hay F, Olsen J, Bobrow L Br J Cancer Suppl. 1991; 14:46-8.

PMID: 1645571 PMC: 2204103.

Differential diagnostic patterns of lung neuroendocrine tumours. A clinico-pathological and immunohistochemical study of 122 cases.

Bonato M, Cerati M, Pagani A, Papotti M, Bosi F, Bussolati G Virchows Arch A Pathol Anat Histopathol. 1992; 420(3):201-11.

PMID: 1372778 DOI: 10.1007/BF01600272.

An immunohistochemical investigation of diagnostic biopsy material taken from short and long term survivors with small cell lung cancer.

Bobrow L, Hirsch F, Hay F, Happerfield L, Skov B, Law K Br J Cancer. 1992; 66(3):547-51.

PMID: 1325828 PMC: 1977947. DOI: 10.1038/bjc.1992.311.

References

Todd 3rd R, Nadler L, Schlossman S . Antigens on human monocytes identified by monoclonal antibodies. J Immunol. 1981; 126(4):1435-42. View

Cerny T, Barnes D, Hasleton P, Barber P, Healy K, Gullick W . Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer. 1986; 54(2):265-9. PMC: 2001525. DOI: 10.1038/bjc.1986.172. View

Epenetos A, Britton K, Mather S, Shepherd J, Granowska M, Taylor-Papadimitriou J . Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet. 1982; 2(8306):999-1005. DOI: 10.1016/s0140-6736(82)90046-0. View

Burchell J, Durbin H, Taylor-Papadimitriou J . Complexity of expression of antigenic determinants, recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells. J Immunol. 1983; 131(1):508-13. View

Wilkinson M, Howell A, Harris M, Taylor-Papadimitriou J, Swindell R, SELLWOOD R . The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. Int J Cancer. 1984; 33(3):299-304. DOI: 10.1002/ijc.2910330304. View

Allan S, Gregor A, Cornbleet M, Leonard R, Smyth J, GRANT I . Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer. Cancer Chemother Pharmacol. 1984; 13(2):106-8. DOI: 10.1007/BF00257124. View

Makin C, Bobrow L, Bodmer W . Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol. 1984; 37(9):975-83. PMC: 498911. DOI: 10.1136/jcp.37.9.975. View

Burchell J, Wang D, Taylor-Papadimitriou J . Detection of the tumour-associated antigens recognized by the monoclonal antibodies HMFG-1 and 2 in serum from patients with breast cancer. Int J Cancer. 1984; 34(6):763-8. DOI: 10.1002/ijc.2910340605. View

Berry N, Jones D, Smallwood J, Taylor I, Kirkham N, Taylor-Papadimitriou J . The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer. Br J Cancer. 1985; 51(2):179-86. PMC: 1977039. DOI: 10.1038/bjc.1985.27. View

10.

Sainsbury J, Farndon J, Sherbet G, Harris A . Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet. 1985; 1(8425):364-6. DOI: 10.1016/s0140-6736(85)91385-6. View

11.

Neal D, Marsh C, Bennett M, Abel P, Hall R, Sainsbury J . Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. 1985; 1(8425):366-8. DOI: 10.1016/s0140-6736(85)91386-8. View

12.

Freedman A, Boyd A, Anderson K, Fisher D, Schlossman S, Nadler L . B5, a new B cell-restricted activation antigen. J Immunol. 1985; 134(4):2228-35. View

13.

Souhami R, Bradbury I, Geddes D, Spiro S, Harper P, Tobias J . Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res. 1985; 45(6):2878-82. View

14.

Sikora K, Evan G, Stewart J, Watson J . Detection of the c-myc oncogene product in testicular cancer. Br J Cancer. 1985; 52(2):171-6. PMC: 1977100. DOI: 10.1038/bjc.1985.174. View

15.

Cole S, Mirski S, McGarry R, Cheng R, Campling B, Roder J . Differential expression of the Leu-7 antigen on human lung tumor cells. Cancer Res. 1985; 45(9):4285-90. View

16.

Cuttitta F, Carney D, Mulshine J, Moody T, Fedorko J, Fischler A . Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 1985; 316(6031):823-6. DOI: 10.1038/316823a0. View

17.

Gullick W, Marsden J, Whittle N, Ward B, Bobrow L, Waterfield M . Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res. 1986; 46(1):285-92. View

18.

Cuttitta F, Rosen S, Gazdar A, Minna J . Monoclonal antibodies that demonstrate specificity for several types of human lung cancer. Proc Natl Acad Sci U S A. 1981; 78(7):4591-5. PMC: 319839. DOI: 10.1073/pnas.78.7.4591. View